163 related articles for article (PubMed ID: 7992464)
1. Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.
Stassar MJ; Vegt PD; Steerenberg PA; van der Meijden AP; Meiring HD; Dessens-Kroon M; Geertzen HG; den Otter W
Urol Res; 1994; 22(3):177-84. PubMed ID: 7992464
[TBL] [Abstract][Full Text] [Related]
2. Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.
De Boer LC; Steerenberg PA; Van der Meijden PM; Van Klingeren B; De Jong WH; Elgersma A; Debruyne FM; Ruitenberg EJ
J Urol; 1992 Nov; 148(5):1577-82. PubMed ID: 1433571
[TBL] [Abstract][Full Text] [Related]
3. Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.
de Boer EC; Steerenberg PA; van der Meijden AP; van Klingeren B; de Jong WH; Debruyne FM; Ruitenberg EJ
Prog Clin Biol Res; 1992; 378():81-93. PubMed ID: 1301589
[TBL] [Abstract][Full Text] [Related]
4. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.
De Boer EC; De Jong WH; Steerenberg PA; Van der Meijden AP; Aarden LA; Debruyne FM; Ruitenberg EJ
In Vivo; 1991; 5(6):671-7. PubMed ID: 1810454
[TBL] [Abstract][Full Text] [Related]
5. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
[TBL] [Abstract][Full Text] [Related]
6. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
7. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
[TBL] [Abstract][Full Text] [Related]
8. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
Zlotta AR; Drowart A; Huygen K; De Bruyn J; Shekarsarai H; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Mascart F; Simon J; Schulman CC; Van Vooren JP
Clin Exp Immunol; 1997 Jul; 109(1):157-65. PubMed ID: 9218839
[TBL] [Abstract][Full Text] [Related]
9. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.
de Boer EC; de Jong WH; van der Meijden AP; Steerenberg PA; Witjes F; Vegt PD; Debruyne FM; Ruitenberg EJ
Urol Res; 1991; 19(1):45-50. PubMed ID: 2028562
[TBL] [Abstract][Full Text] [Related]
10. Production of tumor necrosis factor by intravesical administration of bacillus Calmette Guérin in patients with superficial bladder cancer.
Kim CI; Shin JS; Kim HI; Lee JM; Kim SJ
Yonsei Med J; 1993 Dec; 34(4):356-64. PubMed ID: 8128741
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy--a phase I/II study.
de Reijke TM; de Boer EC; Schamhart DH; Kurth KH
Urol Res; 1997; 25(2):117-20. PubMed ID: 9144878
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
14. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
15. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
16. Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.
de Boer EC; De Reijke TM; Schamhart DH; Vos PC; Kurth KH
Urol Res; 1993; 21(6):423-7. PubMed ID: 8171765
[TBL] [Abstract][Full Text] [Related]
17. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.
van der Meijden AP; Steerenberg PA; van Hoogstraaten IM; Kerckhaert JA; Schreinemachers LM; Harthoorn-Lasthuizen EJ; Hagenaars AM; de Jong WH; Debruijne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1989; 28(4):287-95. PubMed ID: 2784716
[TBL] [Abstract][Full Text] [Related]
18. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
19. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
20. Towards an understanding of the mode of action of Bacillus Calmette-Guérin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin.
van der Sloot E; Kuster S; Böhle A; Braun J; Wood WG
Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):503-11. PubMed ID: 1333824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
